Ocular hypotensive effects of medifoxamine.
Medifoxamine is a novel monoamine re-uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. In human volunteer studies it has been found to reduce significantly intraocular pressure after single oral doses of 300-1000 mg, and to produce a small but statistically significant miosis. Its maximal ocular hypotensive action was less than that of oral timolol 20 mg.
Saleh
S
S
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
Turner
P
P
D000284:Administration, Oral; D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology*; D004311:Double-Blind Method; D005021:Ethylamines / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D011897:Random Allocation; D013999:Timolol / Q000494:pharmacology
D000928:Antidepressive Agents; D005021:Ethylamines; D013999:Timolol; C034065:medifoxamine